Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Assets: 2020-2024

Historic Current Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $249.6 million.

  • Foghorn Therapeutics' Current Assets fell 32.12% to $184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.1 million, marking a year-over-year decrease of 32.12%. This contributed to the annual value of $249.6 million for FY2024, which is 3.92% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Current Assets of $249.6 million as of FY2024, which was up 3.92% from $240.2 million recorded in FY2023.
  • Foghorn Therapeutics' Current Assets' 5-year high stood at $459.6 million during FY2021, with a 5-year trough of $190.7 million in FY2020.
  • Moreover, its 3-year median value for Current Assets was $249.6 million (2024), whereas its average is $280.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 141.00% in 2021, then tumbled by 31.65% in 2023.
  • Foghorn Therapeutics' Current Assets (Yearly) stood at $190.7 million in 2020, then surged by 141.00% to $459.6 million in 2021, then dropped by 23.54% to $351.4 million in 2022, then slumped by 31.65% to $240.2 million in 2023, then grew by 3.92% to $249.6 million in 2024.